# Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)

Source: https://onco.cc/trials/nct02542293/  
OnCo record `nct02542293` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Durvalumab, Tremelimumab, Carboplatin, Gemcitabine + cisplatin, Gemcitabine and Cisplatin in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.

## Summary

Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) is a phase 3 interventional study registered as NCT02542293 by AstraZeneca, with 953 participants enrolled, started 2015-11-03 and due to reach its primary completion in 2020-09-21. Interventions recorded: Durvalumab +Tremelimumab, Paclitaxel + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + cisplatin and Pemetrexed + carboplatin. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Also known as: NEPTUNE
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02542293
- Phase: 3
- Setting: A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC).
- Sponsor: AstraZeneca
- Enrolled: 953
- Outcomes: Overall Survival (OS); Global Cohort: Blood Tumor Mutational Burden (bTMB) ≥20 Mutations Per Megabase (Mut/Mb) Analysis Set: Global: Durvalumab + Tremelimumab 11.7 months vs Global: SoC Chemotherapy 9.1 months, HR 0.71; OS; China Cohort: China Programmed Cell Death Ligand 1 (PD-L1) Negative NSCLC Analysis Set: China: Durvalumab + Tremelimumab 15 months vs China: SoC Chemotherapy 11.7 months, HR 0.6

## Sources

- ClinicalTrials.gov NCT02542293: https://clinicaltrials.gov/study/NCT02542293

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Gemcitabine + cisplatin](https://onco.cc/drugs/gemcitabine-cisplatin/), [Tremelimumab](https://onco.cc/drugs/tremelimumab/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- terms: [Lung cancer: the failed and stopped programmes, and why](https://onco.cc/terms/lung-failed-programmes/)
- trials: [Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).](https://onco.cc/trials/nct03164616/)

---
JSON: https://onco.cc/api/v1/entities/nct02542293.json